Status:
COMPLETED
Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may al...
Detailed Description
OBJECTIVES: * Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy. OUTLINE: Tumor tissue samples collected on clinical tri...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum
- Receiving bevacizumab on clinical trial E-3200
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
July 24 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00897754
Start Date
July 24 2007
End Date
February 1 2009
Last Update
May 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.